Quantcast

U.S. FDA approves anti-psychotic drug

August 1, 2009

Invega Sustenna, a longer-acting anti-psychotic medication for schizophrenia, has been approved by the U.S. Food and Drug Administration, its maker says.

Janssen, a division of Ortho-McNeil-Janssen Pharmaceuticals Inc., said in a release Friday its once-monthly injectable version of the drug paliperidone palmitate became the first of its kind to be approved in the United States.

The approval of once-monthly Invega Sustenna will provide healthcare professionals with a treatment option that is, at the same time, a definitive monitoring tool for uninterrupted medication compliance, which may help optimize clinical outcomes in schizophrenia, said clinical investigator Henry A. Nasrallah, a doctor who worked on the Invega Sustenna trials.

The fact Invega Sustenna must only be taken once a month is important as many schizophrenia sufferers have problems maintaining a steady medication schedule.

There is no cure for schizophrenia, which estimates say affects about 1 percent of the world’s population. The brain disorder, which can be managed via proper medical treatment, leaves patients with problems maintaining social relations, clear thinking and distinguishing reality from imagination.


Source: upi



comments powered by Disqus